Management of XXXX .

@entity1 @entity548 @entity4382 @entity16523 @entity2881 @entity74 @entity942
UNASSIGNED: @entity16523 is the most common @entity74 known. It is caused by a @entity942 of the @entity2881 molecule. Bleeding risk varies between modest increases in @entity548 seen only with procedures to major risk of spontaneous @entity548 depending upon the type of @entity16523 . The treatment approach to @entity16523 has changed little in the past 2 decades, but there are numerous subtleties in optimal management. Management includes the prevention or treatment of @entity548 by raising endogenous @entity2881 levels with medications such as desmopressin or providing exogenous @entity2881 concentrates. Fibrinolytic inhibitors and topical hemostatic agents are also effective adjunctive measures. Bleeding specific to @entity1 presents a special challenge because of heavy @entity548 and pregnancy. Successful management of pregnancy in @entity1 with @entity16523 involves coordination with obstetrics, anesthesia, and the coagulation laboratory monitoring @entity2881 :RCo and FVIII:C levels. Prophylactic treatment with @entity2881 concentrates is emerging as an effective preventive therapy in @entity1 with severe disease. Antibodies to @entity2881 present a special challenge in the management of rare @entity1 with type 3 disease. New therapies on the horizon include recombinant @entity2881 , anti- @entity2881 aptamers, and medications such as @entity4382 to raise @entity2881 levels. The key to effective treatment of @entity16523 is an accurate diagnosis of the specific type and selection of hemostatic products appropriate for the clinical situation.
